All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.

The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your AML Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
Visit:
ALL Hub

ALL Hub

GvHD Hub

GvHD Hub

Lupus Hub

Lupus Hub

Lymphoma Hub

Lymphoma Hub

MPN Hub

MPN Hub

Multiple Myeloma

Multiple Myeloma Hub

PsOPsA Hub

PsOPsA Hub

LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
Steering CommitteeAbout UsNewsletterContact
TypesTherapeuticsCongressesTrialsExpert OpinionsDRUG UPDATES
2022-07-08T15:16:17.000Z

Magrolimab in TP53-mutated AML and MDS: What are the latest updates from EHA2022?

By Marcia Rato, Erika Roa
Featured
Naval Daver
Jul 8, 2022
Share:
Learning objective: After reading this article, learners will be able to cite a new clinical development in AML

Bookmark this article

During the EHA2022 Congress, the AML Hub spoke with Naval Daver, MD Anderson Cancer Center, Houston, US. We asked for the latest updates about magrolimab in TP53-mutated AML and MDS from EHA2022.

Magrolimab in TP53-mutated AML and MDS: What are the latest updates from EHA2022?

Daver discusses a study investigating magrolimab + azacitidine in two patient groups: (1) patients with frontline higher-risk MDS and (2) older patients with AML who are unfit for intensive chemotherapy. Daver discusses the mechanism of action of magrolimab and concludes by outlining efficacy, survival, and adverse effects seen in both study arms.

 

More about...
AML-related mutationsAzacitidineEHA 2022Magrolimab

Your opinion matters

Do you intend to implement next-generation sequencing for measurable residual disease monitoring in MDS patients?
1 vote - 2 days left ...

Related articles

Add bookmark

Which AML patients benefit most from FLT3 inhibitor treatment?

The AML Hub was pleased to speak with Jorge Cortes, Augusta University, Augusta, US. We asked, Which AML patients benefit most from FLT3 inhibitor treatment?

Feb 28, 2022
Add bookmark

Which AML patients benefit most from FLT3 inhibitor treatment?

The AML Hub was pleased to speak with Jorge Cortes, Augusta University, Augusta, US. We asked, Which AML patients benefit most from FLT3...

Feb 28, 2022
Add bookmark

Magrolimab plus azacytidine in patients with myelodysplastic syndromes and acute myeloid leukemia

During the American Society of Clinical Oncology (ASCO) Virtual Meeting 2020, David Sallman from the Moffitt Cancer Center, US, presented an abstract...

Jun 29, 2020
Add bookmark

Magrolimab plus azacytidine in patients with myelodysplastic syndromes and acute myeloid leukemia

During the American Society of Clinical Oncology (ASCO) Virtual Meeting 2020, David Sallman from the...

Jun 29, 2020

Newsletter

Subscribe to get the best content related to AML delivered to your inbox